Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000594921
Ethics application status
Approved
Date submitted
28/04/2020
Date registered
22/05/2020
Date last updated
5/10/2024
Date data sharing statement initially provided
22/05/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Partnering with General practitioners to Optimise Survivorship for PatiEnts with Lymphoma: A Phase II randomised controlled trial.
Scientific title
Partnering with General practitioners to Optimise Survivorship for PatiEnts with Lymphoma: A Phase II randomised controlled trial on effect of shared model of follow-up care on quality of life (The GOSPEL I Trial)
Secondary ID [1] 301111 0
Nil known
Universal Trial Number (UTN)
U1111-1250-8246
Trial acronym
GOSPEL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lymphoma 317200 0
Condition category
Condition code
Cancer 315340 315340 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 315342 315342 0 0
Hodgkin's
Cancer 315341 315341 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Group 1 (The shared-care group):

Both acute post-treatment and observation follow-up patients will be offered 1 x 30-60 minute Nurse-led clinic within 10 weeks after the end of treatment and/or at least 2 weeks prior to the GP case-conference to: 1) provide survivorship patient education including a written survivorship booklet on “Living Well After Treatment – A guide for patients and families” published by Leukaemia Foundation; 2) treatment summary; 3) co-develop a Survivorship Care Plan (SCP) including SMART goals (using motivational interviewing and self-efficacy techniques); and 4) follow-up appointment schedule. A completed draft treatment summary and SCP will be provided to the GP.

Both acute post-treatment and observation follow-up patients will be offered 1 x 20-30 minute case-conference between specialist nurse and GP after the Nurse-led clinic to discuss intervention follow-up schedule, the draft SCP with the GP and negotiate GP role in facilitating SCP goals and surveillance activities. A completed SCP will then be forwarded to the GP and the patient.

After GP case conference, acute post-treatment follow-up patients will be offered 3 x GP appointments (at 3, 9 and 18 months) and 3 x Haematologist appointments (at 6, 12 and 24 months). All appointments will be of variable duration depending on patient need and clinician preference.

After GP case conference, observation follow-up (i.e., surveillance clinics) patients will be offered 2 x GP appointments (at 6 and 18 months) and 2 x Haematologist appointments (at 12 and 24 months). All appointments will be of variable duration depending on patient need and clinician preference.

All GP appointments will be to conduct surveillance activities (i.e., history and physical examination for B-symptoms and order and review of full blood count, urea and electrolytes, liver function tests and lactate dehydrogenase) and review the SCP, general health, and screening/management of comorbidities, psychosocial health cancer treatment toxicities, cancer-related symptoms; chronic disease management planning and allied health referrals. The GP will have direct telephone access to the specialist nurse in case of concerns or escalation for acute care review.

All Haematologist appointments will be to conduct surveillance activities (i.e., history and physical examination for B-symptoms and order and review of full blood count, urea and electrolytes, liver function tests and lactate dehydrogenase).

At 2 years, both acute post-treatment and observation follow-up patients will return to standard care practices (either discharge to GP or continued specialist surveillance).
Intervention code [1] 317557 0
Treatment: Other
Intervention code [2] 317417 0
Behaviour
Comparator / control treatment
Group 2 (Information Only)
Standard follow-up care plus a written survivorship booklet on “Living Well After Treatment – A guide for patients and families” published by Leukaemia Foundation. The current follow-up arrangement is a specialist-led model as determined by the treating Haematologist..
Control group
Active

Outcomes
Primary outcome [1] 323592 0
Health-related quality of life as measured by Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)
Timepoint [1] 323592 0
Measured at baseline, 6 months and 12 months.
Secondary outcome [1] 382304 0
Employment interference as measured by 0-10 numerical analogue scale where 10 is "a great deal" and 0 is "none".
Timepoint [1] 382304 0
Measured at Baseline, 6 months and 12 months
Secondary outcome [2] 382301 0
Sedentary behaviours as measured by a single item of the International Physical Activity Questionnaire (IPAQ)
Timepoint [2] 382301 0
Measured at Baseline, 6 months and 12 months
Secondary outcome [3] 382303 0
Financial distress as measured by 0-10 numerical analogue scale where 10 is "a great deal" and 0 is "none".
Timepoint [3] 382303 0
Measured at Baseline, 6 months and 12 months
Secondary outcome [4] 382306 0
Completed nurse-led clinic (Y/N) as per nurse record in research database (for Intervention group ; Arm 1 only)
Timepoint [4] 382306 0
Measured retrospectively from baseline to 12 months.
Secondary outcome [5] 382840 0
Completed GP case conferencing (Y/N) as per nurse record in research database (for Intervention group ; Arm 1 only)
Timepoint [5] 382840 0
Measured retrospectively from baseline to 12 months.
Secondary outcome [6] 382297 0
Patient experience of care as measured by Patient Assessment of Care for Chronic Conditions (PACIC-20)
Timepoint [6] 382297 0
Measured at baseline, 6 months and 12 months.
Secondary outcome [7] 382300 0
Physical activity behaviours as measured by the Active Australia Survey
Timepoint [7] 382300 0
Measured at Baseline, 6 months and 12 months
Secondary outcome [8] 382299 0
Comorbidity burden as measured by The Charleston Comorbidity Index (CCI) supplemented with items from Self-Administered Comorbidity Questionnaire (SCQ)
Timepoint [8] 382299 0
Measured at Baseline and 12 months
Secondary outcome [9] 382298 0
Symptom distress as measured by Memorial Symptom Assessment Scale (MSAS)
Timepoint [9] 382298 0
Measured at Baseline, 6 months and 12 months
Secondary outcome [10] 382302 0
Dietary intake behaviours as measured by two Short Dietary Questions from the National Nutrition Survey
Timepoint [10] 382302 0
Measured at Baseline, 6 months and 12 months
Secondary outcome [11] 382307 0
Cost-analysis as measured by hospital case mix data describing occasions of service including duration and indication and research nurse records in database and record of all resources required to conduct the intervention (e.g., staff, training, materials, communications, office space, utilities).
Timepoint [11] 382307 0
Measured prospectively and retrospectively from Baseline to 12 months.
Secondary outcome [12] 382841 0
Completed Survivorship Care Plan/components (Y/N) as per nurse record in research database (for Intervention group ; Arm 1 only)
Timepoint [12] 382841 0
Measured retrospectively from baseline to 12 months.
Secondary outcome [13] 382842 0
Number of hospital clinical encounters, unscheduled lymphoma clinic visits and rapid referrals back to acute care as per nurse record in research database (for Intervention group ; Arm 1 only)
Timepoint [13] 382842 0
Measured retrospectively from baseline to 12 months.
Secondary outcome [14] 382305 0
Satisfaction of care as measured by a 0-10 numerical analogue scale with 10 being "most satisfied", supplemented with short, structured qualitative questions.
Timepoint [14] 382305 0
Measured at 12 months.

Eligibility
Key inclusion criteria
Due to the varying follow-up requirements for patients with lymphoma, we will recruit 2 groups of patients who map to 2 distinct follow-up pathways:
- Group 1. Acute post-treatment follow-up: Patients with a pathologically confirmed diagnosis of aggressive or indolent lymphoma in the acute post-treatment phase (i.e., within three months of completion of chemotherapy); and
- Group 2. Observation follow-up (i.e., surveillance clinics): Patients with a pathologically confirmed diagnosis of indolent lymphoma followed up in the surveillance clinic and at least 2 years post-treatment or treatment naïve.

All participants must be:
- Men or women
- >/=18 years of age
- have an ECOG performance status <2
- be an ambulatory patient at the time of recruitment
- be able to nominate a GP to be involved in their follow-up
- have access to a telephone
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- the presence of severe mental, cognitive or physical conditions that would limit the patient’s ability to participate as per treating clinician.
- Lymphoma not in remission

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The allocation code will be kept in a sealed opaque envelope. Allocation will remain concealed from the research nurse and patient until after the patient is consented and baseline data collected.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation (using blocks of 4 and 8) will be conducted to assign participants to the control or intervention arms. To ensure equal distribution of patients with different follow-up schedules, patients will be stratified by diagnosis (NHL vs HL) and follow-up pathway (i.e., post-treatment vs surveillance clinic)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Not applicable
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Descriptive statistics will be used to report on feasibility and process-related elements (e.g., recruitment, intervention, retention rates) as well as clinical and resource outcomes. Preliminary effect size estimates for patient and resource use outcomes will be calculated following intention-to-treat principles using linear mixed models. Models will include group, time and their interaction and be adjusted by diagnosis and age. Balance of demographic variables between usual care and intervention group will be investigated using chi-square and t-test and will be included in the model if found to be both significantly associated with the outcome and confounding the intervention. Assumptions of all models (normality, linearity, homoscedasticity) will be examined using the residuals of the model and will be described using mean, median, skewness, kurtosis and plots such as histograms and QQ-plots. If assumptions are violated, models will be either bootstrapped or log transformation as appropriate.
Hospital resources and costs will be captured using casemix data to understand what resources are used by participants in the hospital system and whether they are different by group allocation. We will analyse resource and cost data using generalised linear models which are suitable for right skewness, are flexible and fit cost data well. This analysis will also assist in understanding the intervention delivery costs and provide data on feasibility of a larger scale full economic evaluation.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
4/01/2021
Actual
13/07/2020
Date of last participant enrolment
Anticipated
31/01/2022
Actual
17/05/2022
Date of last data collection
Anticipated
17/05/2023
Actual
17/05/2023
Sample size
Target
60
Accrual to date
Final
51
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 16542 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 30104 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 305555 0
Hospital
Name [1] 305555 0
Health Innovation, Investment and Research Office (HIIRO) Queensland Advancing Clinical Research Fellowships
Country [1] 305555 0
Australia
Primary sponsor type
Individual
Name
Professor Raymond Chan
Address
Division of Cancer Services
Level 2
199 Ipswich Road
Princess Alexandra Hospital
Woolloongabba
QLD 4102

School of Nursing
N Block Level 3 342
Victoria Park Road
Queensland University of Technology
Kelvin Grove
QLD 4059
Country
Australia
Secondary sponsor category [1] 305961 0
None
Name [1] 305961 0
Address [1] 305961 0
Country [1] 305961 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 305862 0
Metro South Human Research Ethics Committee
Ethics committee address [1] 305862 0
Ethics committee country [1] 305862 0
Australia
Date submitted for ethics approval [1] 305862 0
03/03/2020
Approval date [1] 305862 0
14/04/2020
Ethics approval number [1] 305862 0
HREC/2020/QMS/61872

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 101846 0
Prof Raymond Chan
Address 101846 0
Division of Cancer Services
Level 2
199 Ipswich Road
Princess Alexandra Hospital
Woolloongabba
QLD 4102

School of Nursing
N Block Level 3 342
Victoria Park Road
Queensland University of Technology
Kelvin Grove
QLD 4059
Country 101846 0
Australia
Phone 101846 0
+61 7 31387311
Fax 101846 0
Email 101846 0
Raymond.chan@qut.edu.au
Contact person for public queries
Name 101847 0
Raymond Chan
Address 101847 0
Division of Cancer Services
Level 2
199 Ipswich Road
Princess Alexandra Hospital
Woolloongabba
QLD 4102

School of Nursing
N Block Level 3 342
Victoria Park Road
Queensland University of Technology
Kelvin Grove
QLD 4059
Country 101847 0
Australia
Phone 101847 0
+61 7 31387311
Fax 101847 0
Email 101847 0
Raymond.chan@qut.edu.au
Contact person for scientific queries
Name 101848 0
Raymond Chan
Address 101848 0
Division of Cancer Services
Level 2
199 Ipswich Road
Princess Alexandra Hospital
Woolloongabba
QLD 4102

School of Nursing
N Block Level 3 342
Victoria Park Road
Queensland University of Technology
Kelvin Grove
QLD 4059
Country 101848 0
Australia
Phone 101848 0
+61 7 31387311
Fax 101848 0
Email 101848 0
Raymond.chan@qut.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbasePartnering with general practitioners to optimize survivorship for patients with lymphoma: a phase II randomized controlled trial (the GOSPEL I trial).2021https://dx.doi.org/10.1186/s13063-020-04945-4
N.B. These documents automatically identified may not have been verified by the study sponsor.